Rituximab for worsening inflammatory lung scarring
Treatments studied
Part of Lungs & breathing clinical trials.
This trial studies whether rituximab can slow worsening lung scarring (interstitial lung disease) when there is an inflammatory component. You would get rituximab or a placebo (inactive treatment) in a blinded, randomized design to compare safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your lung disease has been getting worse in the last 24 months based on breathing tests, symptoms, or scans
- Your lung samples show an “inflammatory” pattern (for example, certain immune-cell findings on biopsy or fluid test results)
- You can take part safely and follow study visits, and you agree in writing
- You live in France and are covered by French social security
- You have not already had rituximab for this kind of condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This trial tests a treatment for people with advanced non-small cell lung cancer who also have interstitial lung disease (a type of lung scarring). It aims to find out if the treatment is safe and effective for this specific group of patients.
This Phase 3 trial studies whether glucocorticoid (steroid) medicine helps people with idiopathic pulmonary fibrosis (IPF) who have a sudden flare-up, compared with an inactive placebo. You may be helped if steroids improve breathing and recovery during these acute episodes, but the study is designed to test that clearly.
This study tests a treatment plan for people who have rheumatoid arthritis and interstitial lung disease (scarring in the lungs). The goal is to find the best way to treat both conditions together and slow lung damage.
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
Hear when a new Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.